Drug Profile
A 166
Alternative Names: A-166Latest Information Update: 11 Jul 2022
Price :
$50
*
At a glance
- Originator Klus Pharma
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer
- Phase I/II Solid tumours
Most Recent Events
- 11 Jul 2022 Phase-II clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater) in China (IV) (KLUS Pharma pipeline, July 2022)
- 03 Jun 2022 Updated safety and efficacy data from a phase I trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 01 Jun 2022 Efficacy data from a phase I trial in Solid tumours released by Sichuan Kelun-Biotech Biopharmaceutical